An experimental model of chronic renal allograft rejection in SD-Wistar rats

doi:10.3969/j.issn.2095-4344.2015.40.023

Abstract

Abstract:

BACKGROUND: Fisher-Lewis rat kidney transplant models are the international common chronic renal allograft rejection models, but their application is greatly limited because of difficulty in model preparation and high costs.

OBJECTIVE: To explore a new method of establishing SD-Wistar rat models of chronic renal allograft rejection.

METHODS: Fifty-six pairs of SD-Wistar rats were subjected to left kidney orthotopic transplantation. The right kidneys of the recipients were intact and used as internal controls. 23 rat recipients were randomly divided into model group (n=15) and control group (n=8). The rats in the model group were injected with cyclosporine microemulsion for 10 days (2 mg/kg/day,i.p.) after kidney transplantation. The rats in the control group were not treated with immunosuppressive therapy.

RESULTS AND CONCLUSION: The irreversible acute rejection occurred in all the transplanted kidneys of rats in the control group within 4 weeks, leading to the necrosis of transplanted kidney. Moderate inflammatory cell infiltration appeared in the transplanted kidneys of rats in the model group at 4, 8 and 12 weeks after transplantation. Typical histopathological changes of chronic rejection were observed within 12 weeks after transplantation. The Banff total scores were increased with time after transplantation. All these histopathological changes were not observed in the intact right kidneys of rat recipients in both groups. The valley value of cyclosporine concentration in the transplanted rats in the model group was (153.2±17.1) μg/L at 4 days after transplantation. These results demonstrate that after a short course treatment of cyclosporine microemulsion (2 mg/kg/day for 10 days, i.p.) in SD-Wistar rat recipients, moderate inflammatory cell infiltration was followed by development of chronic rejection within 12 weeks, and such animal models can be used for studying chronic renal allograft rejection.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Key words: Transplantation, Kidney Transplantation, Graft Rejection, Cyclosporine

CLC Number:

R318

Yu Peng-cheng, Liu Yong-guang, Guo Ying, Li Min, Xiao Zong-yu, Hu Kong-he, Huang Jin-jun, Xin Jun, Wu Zhi-qiang, Zhao Ming. An experimental model of chronic renal allograft rejection in SD-Wistar rats[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(40): 6520-6525.

Figures/Tables 3

References

[1] Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation. 2002;73(12):1923-1928.
[2] Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation. 1992;54(4):710-716.
[3] Yilmaz S, Paavonen T, Häyry P. Chronic rejection of rat renal allografts. II. The impact of prolonged ischemia time on transplant histology. Transplantation. 1992;53(4): 823-827.
[4] Soots A, Lautenschlager I, Krogerus L, et al. An experimental model of chronic renal allograft rejection in the rat using triple drug immunosuppression. Transplantation. 1998;65(1):42-46.
[5] Rintala JM, Savikko J, Rintala SE, et al. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts. Nephrol Dial Transplant. 2008;23(11):3446-3455.
[6] Pascual J. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors. Transplantation. 2005;79(9 Suppl):S76-79.
[7] Kahan BD. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplantation. 2001;71(11 Suppl):SS52-57.
[8] Tedesco Silva H Jr, Pinheiro Machado P, Rosso Felipe C, et al. Immunotherapy for De Novo renal transplantation: what's in the pipeline? Drugs. 2006;66(13):1665-1684.
[9] Press RR, de Fijter JW, Guchelaar HJ. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives. Curr Pharm Des. 2010;16(2): 176-186.
[10] Wali RK, Weir MR. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant. 2008;13(6):614-621.
[11] Silber SJ, Crudop J. Kidney transplantation in inbred rats. Am J Surg. 1973;125(5):551-553.
[12] Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-760.
[13] Fisher B, Lee S. Microvascular surgical techniques in research, with special reference to the renal transplantation in the rat. Surgery. 1965;58(5):904-914.
[14] Yin JL, Pilmore HL, Yan YQ, et al. Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection. Transplantation. 2002; 73(4):657-660.
[15] Yanagita M. The role of the vitamin K-dependent growth factor Gas6 in glomerular pathophysiology. Curr Opin Nephrol Hypertens. 2004;13(4):465-470.
[16] Coito AJ, Kupiec-Weglinski JW. Extracellular matrix proteins: bystanders or active participants in the allograft rejection cascade? Ann Transplant. 1996;1(3):14-18.
[17] Wu KS, Hung YJ, Lee CH, et al. The Involvement of GAS6 Signaling in the Development of Obesity and Associated Inflammation. Int J Endocrinol. 2015;2015:202513.
[18] Mackenzie HS, Tullius SG, Heemann UW, et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest. 1994;94(5):2148-2152.
[19] Kujal P, Vernerová Z. 5/6 nephrectomy as an experimental model of chronic renal failure and adaptation to reduced nephron number. Cesk Fysiol. 2008;57(4):104-109.
[20] Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech. 2002;57(4):189-195.
[21] 辛宇鹏,卢一平,张秀辉,等.大鼠原位异体肾移植硬化加快模型的建立[J].四川大学学报(医学版),2004,35(2):267-270.
[22] Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int Suppl. 1995;52:S63-69.
[23] Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy in renal transplantation. Transplant Proc. 1996;28(4):2100-2103.
[24] Wiecek A, Nowicki M, Kokot F, et al. Acute failure of the transplanted kidney--pathophysiology, diagnosis and prevention. Ann Transplant. 1996;1(4):5-9.
[25] Katznelson S, Wilkinson A, Rosenthal TR, et al. Cyclosporine-induced hemolytic uremic syndrome: factors that obscure its diagnosis. Transplant Proc. 1994;26(5):2608- 2609.
[26] 刘小友,于立新,付绍杰,等.大鼠肾移植急性排斥反应模型的建立[J].中华泌尿外科杂志,2005,26(11):730-732.
[27] Paul LC. Functional and histologic characteristics of chronic renal allograft rejection. Clin Transplant. 1994;8(3 Pt 2): 319-323.
[28] Häyry P, Isoniemi H, Yilmaz S, et al. Chronic allograft rejection. Immunol Rev. 1993;134:33-81.
[29] Paul LC. Animal models of chronic heart and kidney allograft rejection. Transplant Proc. 1993;25(2):2080-2081.
[30] Paul LC, Hayry P, Foegh M, et al. Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc. 1993;25(2):2022-2023.
[31] Kirklin JK, Bourge RC, McGiffin DC. Recurrent or persistent cardiac allograft rejection: therapeutic options and recommendations. Transplant Proc. 1997;29(8A):40S-44S.
[32] Steinbrüchel DA. Pathogenesis and mechanisms of graft rejection in concordant xenotransplantation with special reference to hamster-to-rat cardiac transplantation. APMIS Suppl. 1996;58:5-45.
[33] Yilmaz S, Taskinen E, Häyry P, et al. Protocol core biopsy as intermediate efficacy end-point in chronic kidney allograft rejection. Transplant Proc. 1996;28(1):491-493.
[34] Demetris AJ, Murase N, Lee RG, et al. Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant. 1997;2(2):27-44.
[35] Cramer DV, Chapman FA, Makowka L. Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium. Transplant Proc. 1993;25(3 Suppl 2): 23-28.
[36] Wanders A, Akyürek ML, Waltenberger J, et al. Impact of ischemia time on chronic vascular rejection in the rat--effects of angiopeptin. Transplant Proc. 1993;25(2):2098-2099.